---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-269387"
form_type: "8-K"
ticker: "JANX"
cik: "0001817713"
company_name: "Janux Therapeutics, Inc."
filed_at: "2026-06-12T20:06:06+00:00"
generated_at: "2026-06-12T20:17:45.898032+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Janux Therapeutics shareholders elect directors, ratify auditor, approve Say-on-Pay at 2026 meeting

## Summary
- Natasha Hernday and Eric Dobmeier elected as Class II directors; Hernday received 42.85M votes for, Dobmeier 46.28M.
- Ernst & Young ratified as independent auditor for FY2026 with 53.56M votes for, 113k against.
- Advisory vote on named executive officer compensation passed with 42.75M For, 4.57M Against, 46k abstentions.
- Total shares outstanding 60.96M; 53.74M shares represented at the meeting (88% quorum).

## SEC filing metadata
- accession: 0001193125-26-269387
- form_type: 8-K
- ticker: JANX
- cik: 0001817713
- company_name: Janux Therapeutics, Inc.
- filed_at: 2026-06-12T20:06:06+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1817713/000119312526269387/0001193125-26-269387-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1817713/000119312526269387/janx-20260611.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-269387
- JSON: https://secwatch.observer/filing/0001193125-26-269387.json
- Plain text: https://secwatch.observer/filing/0001193125-26-269387.txt

## Key facts
- Shareholder Votes
  Janux Therapeutics, Inc. shareholders approved Advisory Vote on Executive Compensation at the 2026-06-11 meeting.
  - Proposal: say on pay
  - Outcome: passed
  - Meeting: 2026-06-11
  source text: Proposal 3: Advisory Vote on Executive Compensation The Company’s stockholders approved, on an advisory (non-binding) basis, the compensation of our named executive officers as disclosed in the Proxy Statement. The final voting results are as follows: Votes For Votes Against Abstentions Broker Non-Votes 42,749,182 4,574,376 46,341 6,375,023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1817713/000119312526269387/0001193125-26-269387-index.htm
- Shareholder Votes
  Janux Therapeutics, Inc. shareholders approved Ratification of the Selection of Independent Registered Public Accounting Firm at the 2026-06-11 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2026-06-11
  source text: Proposal 2: Ratification of the Selection of Independent Registered Public Accounting Firm The Company’s stockholders ratified the selection by the Audit Committee of the Company’s Board of Directors of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The final voting results are as follows: Votes For Votes Against Abstentions 53,560,969 113,446 70,507
  evidence_url: https://www.sec.gov/Archives/edgar/data/1817713/000119312526269387/0001193125-26-269387-index.htm
- Shareholder Votes
  Janux Therapeutics, Inc. shareholders approved Election of Directors at the 2026-06-11 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2026-06-11
  source text: Proposal 1: Election of Directors The Company’s stockholders elected the two persons listed below as Class II directors, each to serve until the Company’s 2029 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified, or until their earlier death, resignation or removal. The final voting results are as follows: Name of Director Elected Votes For Votes Withheld Broker Non-Votes Natasha Hernday 42,850,103 4,519,796 6,375,023 Eric Dobmeier 46,279,387 1,090,512 6,375,023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1817713/000119312526269387/0001193125-26-269387-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.